Nemolizumab is a first-in-class monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31. 2 IL-31 is a neuroimmune cytokine that drives itch and is ...
No significant differences in clinical outcomes were observed between ABP 654 and ustekinumab reference product in patients with plaque psoriasis, including among patients who transitioned from ...